{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:59Z","timestamp":1793050979874,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>CD22 is a surface molecule expressed early during the ontogeny of B cells in the bone marrow and spleen, and can be found on B cells isolated from the different lymphoid compartments in humans. CD22 is expressed by most blasts from the majority (60\u201390%) of B-cell acute lymphoblastic leukemia (B-ALL). Current therapies in adults with newly diagnosed B-ALL are associated with complete remission (CR) rates of 50\u201390%. However, 30\u201360% of these patients relapse, and only 25\u201340% achieve disease-free survival of three years or more. Chemotherapy regimens for patients with refractory\/relapsed B-ALL are associated with CR rates ranging from 31% to 44%. Novel immune-targeted therapies, such as blinatumomab and inotuzumab (a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin), provide potential means of circumventing chemo-refractory B-ALL cells through novel mechanisms of action. Eighty percent of inotuzumab-treated B-ALL patients may achieve a CR state. This review is focused on the biological and clinical activities of CD22 antibodies in B-ALL, and provides evidence about the potential role played by qualitative and quantitative analysis of the CD22 molecule on individual B-ALL blasts in predicting the depletion of leukemic cells, and, ultimately, leading to better clinical response rates.<\/jats:p>","DOI":"10.3390\/cancers12020303","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T09:37:09Z","timestamp":1580204229000},"page":"303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-7167","authenticated-orcid":false,"given":"Francesco","family":"Lanza","sequence":"first","affiliation":[{"name":"Hematology Unit &amp; Romagna Transplant Network, Ravenna Hospital, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maffini","sequence":"additional","affiliation":[{"name":"Hematology Unit &amp; Romagna Transplant Network, Ravenna Hospital, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[{"name":"Hematology Unit &amp; Romagna Transplant Network, Ravenna Hospital, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2502-7395","authenticated-orcid":false,"given":"Evita","family":"Massari","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, Hub Laboratory, Romagna Transplant Network, 47522 Cesena (FC), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Corso","family":"Faini","sequence":"additional","affiliation":[{"name":"Department of Medical Science, University of Torino and Fondazione Ricerca Molinette, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[{"name":"Department of Medical Science, University of Torino and Fondazione Ricerca Molinette, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"ref_2","first-page":"85","article-title":"Treatment of Adult Patients with Relapsed\/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia","volume":"1","author":"Maffini","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of Acute Lymphoblastic Leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3324\/haematol.2018.207506","article-title":"How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"104","author":"Frisch","year":"2019","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/asheducation-2018.1.9","article-title":"Antibody-based therapies in patients with acute lymphoblastic leukemia","volume":"1","author":"Dinner","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/cyto.b.21644","article-title":"Issue Highlight\u2014July 2018","volume":"94","author":"Lanza","year":"2018","journal-title":"Cytometry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ni1121","article-title":"CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms","volume":"5","author":"Poe","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_10","first-page":"61","article-title":"Analysis of Ten B Lymphocyte-Specific Workshop Monoclonal Antibodies","volume":"Volume 2","author":"Reinherz","year":"1986","journal-title":"Leukocytes Typing II"},{"key":"ref_11","first-page":"3","article-title":"B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding","volume":"2820","author":"Meyer","year":"2018","journal-title":"Front Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.it.2012.04.010","article-title":"CD22 and Siglec-G in B cell function and tolerance","volume":"33","author":"Poe","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(05)88001-0","article-title":"CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction","volume":"88","author":"Tedder","year":"2005","journal-title":"Adv. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ni1283","article-title":"Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling","volume":"7","author":"Collins","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by Antibodies: Recent Progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/eji.201141899","article-title":"CD22 serves as a receptor for soluble IgM","volume":"42","author":"Adachi","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1093\/annonc\/mdx541","article-title":"The antibody-drug conjugate target landscape across a broad range of tumour types","volume":"28","author":"Moek","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Sicard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/HAB-160305","article-title":"Antibody mimicry, receptors and clinical applications","volume":"25","author":"Horenstein","year":"2017","journal-title":"Hum. Antibodies"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2567.2007.02791.x","article-title":"Dependence of surface monoclonal antibody binding on dynamic changes in Fc gamma RIIb expression","volume":"124","author":"Walker","year":"2008","journal-title":"Immunology"},{"key":"ref_21","first-page":"e1574198","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD","volume":"7","author":"Morandi","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_22","first-page":"E39","article-title":"\u03b3\u03b4 T cells affect IL-4 production and B-cell tolerance","volume":"112","author":"Huang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1084\/jem.20011435","article-title":"Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fc gamma RII-mediated B cell suppression","volume":"195","author":"Rudge","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: A phase 1\/2 study","volume":"1","author":"Stock","year":"2017","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"Inotuzumab: From preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: Results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: A CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3892\/ijo_00000638","article-title":"Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line","volume":"36","author":"Cianfriglia","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-019-0211-y","article-title":"ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: A report from Children\u2019s Oncology Group AAML0531 Trial","volume":"9","author":"Rafiee","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab Ozogamicin Versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long-Term Survival Follow-Up From the Randomized, Phase 3 INO-VATE Study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini\u2013hyper-CVD for patients with relapsed or refractory philadelphia chromosome\u2013negative acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., and Basak, G. (2019). Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A position statement from an international expert group. Bone Marrow Transplant.","DOI":"10.1038\/s41409-019-0705-z"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2019-125340","article-title":"SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed\/Refractory CD22+ Acute Leukemia","volume":"134","author":"Advani","year":"2019","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1182\/blood-2019-125165","article-title":"Inotuzumab Ozogamicin Is An Effective Salvage Therapy in Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.21482","article-title":"A Novel Flow Cytometric Assay for Detection of Residual Disease in Patients with B-Lymphoblastic Leukemia\/Lymphoma Post Anti-CD19 Therapy","volume":"94B","author":"Cherian","year":"2018","journal-title":"Cytometry Part B"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.beha.2018.09.015","article-title":"Should immunologic strategies be incorporated into frontline ALL therapy?","volume":"31","author":"Rank","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","article-title":"Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions","volume":"3","author":"Ravetch","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-0260","article-title":"Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy","volume":"25","author":"Malavasi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fan, Y.Y., Farrokhi, V., Caiazzo, T., Wang, M., O\u2019Hara, D.M., and Neubert, H. (2019). Human FcRn Tissue Expression Profile and Half-Life in PBMCs. Biomolecules, 9.","DOI":"10.3390\/biom9080373"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/psp4.12461","article-title":"A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics from In Vitro Data","volume":"8","author":"Jones","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cpt.1619","article-title":"A minimal physiologically-based pharmacokinetic model demonstrates role of FcRn competition in drug-disease interactions with antibody therapy","volume":"107","author":"Abdallah","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"ref_52","first-page":"155","article-title":"Advances in off-the-shelf CAR T-cell therapy","volume":"17","author":"Benjamin","year":"2019","journal-title":"Clin. Adv. Hematol Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41375-019-0536-3","article-title":"In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab","volume":"34","author":"Atanackovic","year":"2020","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:44:46Z","timestamp":1760363086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cancers12020303"],"URL":"https:\/\/doi.org\/10.3390\/cancers12020303","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]}}}